![]() ![]() The off-label use of bevacizumab (Genentech Inc, San Francisco, CA, USA) is also common practice by retinal specialists worldwide. Four agents have been subsequently approved by the FDA, pegaptanib (OSI Pharmaceuticals, Long Island, NY, USA), ranibizumab (Genentech Inc, San Francisco, CA, USA), aflibercept (Regeneron, Tarrytown, NJ, USA) and brolucizumab (Novartis, Basel, Switzerland). The introduction of the intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents was a major paradigm shift for the management of patients suffering from nAMD by providing efficacious and safe treatment to preserve vision. Exudation, fluid accumulation and haemorrhages from the vessels can result in vision loss, via RPE detachment or subretinal fibrosis if not promptly treated. Neovascular AMD (nAMD), also known as wet or exudative AMD is characterized by the growth of new, abnormal vasculature from the choriocapillaris extending into the retina, threatening the photoreceptors or retinal pigment epithelium (RPE). Future data will continue to investigate faricimab for real-world patients with nAMD. It has been well-tolerated with low incidence of treatable intraocular inflammation. ![]() Conclusionsįaricimab has demonstrated improvement or maintenance of visual acuity for patients with nAMD, along with rapid improvement of anatomical parameters. One case of infectious endophthalmitis was treated with intravitreal antibiotics and resolved. One case of intraocular inflammation was observed after four injections of faricimab and resolved with topical steroids. Secondary outcome measures included treatment intervals and presence of retinal fluid. The main outcome measures are changes in BCVA, changes in central subfield thickness (CST) and adverse events. Collected data includes background demographics, treatment history, best-corrected visual acuity (BCVA), anatomic changes, and adverse events as safety markers. Multicenter, retrospective chart review was conducted on patients treated with faricimab for nAMD from February 2022 to September 2022. Investigate real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |